MWNA
PRLD icon

Marshall Wace North America’s Prelude Therapeutics PRLD Stock Holding History

Marshall Wace North America’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-34,383
Closed -$1.04M – 1524
2020
Q3 		$1.04M Buy
+34,383
New +$971K 0.01% 795

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Marshall Wace North America's PRLD Position: Q4 2020 in Review

Marshall Wace North America sold out of Prelude Therapeutics (PRLD) in Q4 2020, closing a stake of 34,383 shares — an estimated $1.04M sold.

Marshall Wace North America first reported a position in PRLD in Q3 2020 and held it in 1 quarter. The position peaked at $1.04M in Q3 2020. 51 funds tracked by Wall St. Rank hold PRLD as of Q4 2020.

  • Marshall Wace North America reported no remaining Prelude Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Marshall Wace North America sold 34,383 Prelude Therapeutics shares in Q4 2020, an estimated $1.04M.
  • Marshall Wace North America first reported a position in Prelude Therapeutics in Q3 2020 and held it in 1 quarter.
  • Marshall Wace North America's Prelude Therapeutics position peaked at $1.04M in Q3 2020.
  • 51 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.